The UAE Ministry of Health has reduced the prices of 115 drugs in the country, in cooperation with pharmaceutical companies.

The department told a press conference yesterday the move represents its commitment to support the partnership strategies between the Ministry of Health and local and international pharmaceutical companies.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Emirates 24/7 quoted Assistant Undersecretary for Medical Practices and Licensing Dr. Amin Hussein Al Amiri as saying: "The Ministry encourages investment in the private health sector through encouraging such strategic partnerships based on trust, communication and transparency."

The ministry hopes the drug price reduction, the second in the UAE, will encourage investment in the health sector through solid partnerships.

In June 2011, it was announced the price 565 drugs, including those made by Pfizer and Merck Sharp & Dohme for the treatment of serious illnesses, would be cut by 20%.

From September, 103 drugs under GlaxoSmithKline were made available at reduced prices for the general public.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact